Therapeutic area intelligence for Cholesterol Management with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Sciegen Pharmaceuticals →

Assets

FDA →

Lipfendra →

Recent signals(3)

RegulatoryJuly 31, 2026

FDA Approves Supplement for Atorvastatin Calcium by Sciegen Pharmaceuticals

The FDA has approved a supplemental application for atorvastatin calcium submitted by Sciegen Pharmaceuticals.

CompetitiveJuly 18, 2026

FDA Approves First Oral PCSK9 Inhibitor Lipfendra for High Cholesterol

The FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults.

RegulatoryJuly 7, 2026

FDA Grants Approval for Atorvastatin Calcium Supplement

The FDA has granted approval for the atorvastatin calcium supplement submitted by Sciegen Pharmaceuticals.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.